Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Procleix WNV approval

This article was originally published in The Gray Sheet

Executive Summary

FDA announces approval of the Procleix West Nile Virus assay biologic license application Dec. 1. The Gen-Probe test will be marketed by Chiron. Since 2003, the assay has been used for WNV screening by facilities, including the American Red Cross, under an investigational new drug application. The test will now be offered at commercial pricing levels, instead of at cost-recovery levels, Chiron says. Although the assay is approved for use with the Procleix enhanced semi-automated system, the firms are seeking clearance for the fully automated Tigris system, which can handle individual donor screening in areas that have reached an infection threshold when pooled sample testing is insufficient...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT022985

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel